IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

A Calcinotto; C Spataro; E Zagato; D Di Mitri; V Gil; M Crespo; G De Bernardis; M Losa; M Mirenda; E Pasquini; A Rinaldi; S Sumanasuriya; MB Lambros; A Neeb; R Lucianò; CA Bravi; D Nava-Rodrigues; D Dolling; T Prayer-Galetti; A Ferreira; A Briganti; A Esposito; S Barry; W Yuan; A Sharp; J De Bono; A Alimonti

doi:10.1038/s41586-018-0266-0

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

A Calcinotto, C Spataro, E Zagato, D Di Mitri, V Gil, M Crespo, G De Bernardis, M Losa, M Mirenda, E Pasquini, A Rinaldi, S Sumanasuriya, MB Lambros, A Neeb, R Lucianò, CA Bravi, D Nava-Rodrigues, D Dolling, T Prayer-Galetti, A FerreiraA Briganti, A Esposito, S Barry, W Yuan, A Sharp, J De Bono, A Alimonti

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control the development of CRPC remains an unmet clinical need. The well-established dependency of cancer cells on the tumour microenvironment indicates that the microenvironment might control the emergence of CRPC. Here we identify IL-23 produced by myeloid-derived suppressor cells (MDSCs) as a driver of CRPC in mice and patients with CRPC. Mechanistically, IL-23 secreted by MDSCs can activate the androgen receptor pathway in prostate tumour cells, promoting cell survival and proliferation in androgen-deprived conditions. Intra-tumour MDSC infiltration and IL-23 concentration are increased in blood and tumour samples from patients with CRPC. Antibody-mediated inactivation of IL-23 restored sensitivity to androgen-deprivation therapy in mice. Taken together, these results reveal that MDSCs promote CRPC by acting in a non-cell autonomous manner. Treatments that block IL-23 can oppose MDSC-mediated resistance to castration in prostate cancer and synergize with standard therapies. © 2018 Macmillan Publishers Ltd., part of Springer Nature.

Original language	English
Pages (from-to)	363-369
Number of pages	7
Journal	Nature
Volume	559
Issue number	7714
DOIs	https://doi.org/10.1038/s41586-018-0266-0
Publication status	Published - 2018

Access to Document

10.1038/s41586-018-0266-0

http://www.scopus.com/inward/record.url?scp=85050195109&partnerID=8YFLogxK

Fingerprint Dive into the research topics of 'IL-23 secreted by myeloid cells drives castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this

Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., Rinaldi, A., Sumanasuriya, S., Lambros, MB., Neeb, A., Lucianò, R., Bravi, CA., Nava-Rodrigues, D., Dolling, D., Prayer-Galetti, T., ... Alimonti, A. (2018). IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature, 559(7714), 363-369. https://doi.org/10.1038/s41586-018-0266-0

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. / Calcinotto, A; Spataro, C; Zagato, E; Di Mitri, D; Gil, V; Crespo, M; De Bernardis, G; Losa, M; Mirenda, M; Pasquini, E; Rinaldi, A; Sumanasuriya, S; Lambros, MB; Neeb, A; Lucianò, R; Bravi, CA; Nava-Rodrigues, D; Dolling, D; Prayer-Galetti, T; Ferreira, A; Briganti, A ; Esposito, A; Barry, S; Yuan, W; Sharp, A; De Bono, J; Alimonti, A.

In: Nature, Vol. 559, No. 7714, 2018, p. 363-369.

Research output: Contribution to journal › Article › peer-review

Calcinotto, A, Spataro, C, Zagato, E, Di Mitri, D, Gil, V, Crespo, M, De Bernardis, G, Losa, M, Mirenda, M, Pasquini, E, Rinaldi, A, Sumanasuriya, S, Lambros, MB, Neeb, A, Lucianò, R, Bravi, CA, Nava-Rodrigues, D, Dolling, D, Prayer-Galetti, T, Ferreira, A, Briganti, A , Esposito, A, Barry, S, Yuan, W, Sharp, A, De Bono, J & Alimonti, A 2018, 'IL-23 secreted by myeloid cells drives castration-resistant prostate cancer', Nature, vol. 559, no. 7714, pp. 363-369. https://doi.org/10.1038/s41586-018-0266-0

Calcinotto, A ; Spataro, C ; Zagato, E ; Di Mitri, D ; Gil, V ; Crespo, M ; De Bernardis, G ; Losa, M ; Mirenda, M ; Pasquini, E ; Rinaldi, A ; Sumanasuriya, S ; Lambros, MB ; Neeb, A ; Lucianò, R ; Bravi, CA ; Nava-Rodrigues, D ; Dolling, D ; Prayer-Galetti, T ; Ferreira, A ; Briganti, A ; Esposito, A ; Barry, S ; Yuan, W ; Sharp, A ; De Bono, J ; Alimonti, A. / IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. In: Nature. 2018 ; Vol. 559, No. 7714. pp. 363-369.

@article{fb606954b67c48d5a46c7023c24645a3,

title = "IL-23 secreted by myeloid cells drives castration-resistant prostate cancer",

abstract = "Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control the development of CRPC remains an unmet clinical need. The well-established dependency of cancer cells on the tumour microenvironment indicates that the microenvironment might control the emergence of CRPC. Here we identify IL-23 produced by myeloid-derived suppressor cells (MDSCs) as a driver of CRPC in mice and patients with CRPC. Mechanistically, IL-23 secreted by MDSCs can activate the androgen receptor pathway in prostate tumour cells, promoting cell survival and proliferation in androgen-deprived conditions. Intra-tumour MDSC infiltration and IL-23 concentration are increased in blood and tumour samples from patients with CRPC. Antibody-mediated inactivation of IL-23 restored sensitivity to androgen-deprivation therapy in mice. Taken together, these results reveal that MDSCs promote CRPC by acting in a non-cell autonomous manner. Treatments that block IL-23 can oppose MDSC-mediated resistance to castration in prostate cancer and synergize with standard therapies. {\textcopyright} 2018 Macmillan Publishers Ltd., part of Springer Nature.",

author = "A Calcinotto and C Spataro and E Zagato and {Di Mitri}, D and V Gil and M Crespo and {De Bernardis}, G and M Losa and M Mirenda and E Pasquini and A Rinaldi and S Sumanasuriya and MB Lambros and A Neeb and R Lucian{\`o} and CA Bravi and D Nava-Rodrigues and D Dolling and T Prayer-Galetti and A Ferreira and A Briganti and A Esposito and S Barry and W Yuan and A Sharp and {De Bono}, J and A Alimonti",

year = "2018",

doi = "10.1038/s41586-018-0266-0",

language = "English",

volume = "559",

pages = "363--369",

journal = "Nature",

issn = "0028-0836",

publisher = "Nature Publishing Group",

number = "7714",

}

TY - JOUR

T1 - IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

AU - Calcinotto, A

AU - Spataro, C

AU - Zagato, E

AU - Di Mitri, D

AU - Gil, V

AU - Crespo, M

AU - De Bernardis, G

AU - Losa, M

AU - Mirenda, M

AU - Pasquini, E

AU - Rinaldi, A

AU - Sumanasuriya, S

AU - Lambros, MB

AU - Neeb, A

AU - Lucianò, R

AU - Bravi, CA

AU - Nava-Rodrigues, D

AU - Dolling, D

AU - Prayer-Galetti, T

AU - Ferreira, A

AU - Briganti, A

AU - Esposito, A

AU - Barry, S

AU - Yuan, W

AU - Sharp, A

AU - De Bono, J

AU - Alimonti, A

PY - 2018

Y1 - 2018

N2 - Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control the development of CRPC remains an unmet clinical need. The well-established dependency of cancer cells on the tumour microenvironment indicates that the microenvironment might control the emergence of CRPC. Here we identify IL-23 produced by myeloid-derived suppressor cells (MDSCs) as a driver of CRPC in mice and patients with CRPC. Mechanistically, IL-23 secreted by MDSCs can activate the androgen receptor pathway in prostate tumour cells, promoting cell survival and proliferation in androgen-deprived conditions. Intra-tumour MDSC infiltration and IL-23 concentration are increased in blood and tumour samples from patients with CRPC. Antibody-mediated inactivation of IL-23 restored sensitivity to androgen-deprivation therapy in mice. Taken together, these results reveal that MDSCs promote CRPC by acting in a non-cell autonomous manner. Treatments that block IL-23 can oppose MDSC-mediated resistance to castration in prostate cancer and synergize with standard therapies. © 2018 Macmillan Publishers Ltd., part of Springer Nature.

AB - Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control the development of CRPC remains an unmet clinical need. The well-established dependency of cancer cells on the tumour microenvironment indicates that the microenvironment might control the emergence of CRPC. Here we identify IL-23 produced by myeloid-derived suppressor cells (MDSCs) as a driver of CRPC in mice and patients with CRPC. Mechanistically, IL-23 secreted by MDSCs can activate the androgen receptor pathway in prostate tumour cells, promoting cell survival and proliferation in androgen-deprived conditions. Intra-tumour MDSC infiltration and IL-23 concentration are increased in blood and tumour samples from patients with CRPC. Antibody-mediated inactivation of IL-23 restored sensitivity to androgen-deprivation therapy in mice. Taken together, these results reveal that MDSCs promote CRPC by acting in a non-cell autonomous manner. Treatments that block IL-23 can oppose MDSC-mediated resistance to castration in prostate cancer and synergize with standard therapies. © 2018 Macmillan Publishers Ltd., part of Springer Nature.

U2 - 10.1038/s41586-018-0266-0

DO - 10.1038/s41586-018-0266-0

M3 - Article

VL - 559

SP - 363

EP - 369

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7714

ER -